Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Jun 24, 2022 7:23pm
211 Views
Post# 34781694

RE:Bioasis Connections

RE:Bioasis ConnectionsI see so many things at Bioasis to leverage into valuable initiatives. I understand how much hope there is in that. But when I see a lousy press release like the Cresence PR, that didn't anticipate for a moment that it could mean to shareholders that xB3 is being back-shelved, or lowered in importance, which it's not, then I wonder whether there is a thought of any kind being given to anticipating shareholder reactions to anything.

That PR should have mentioned that the new technology is a small molecule (a peptide????), that a P2 clinical trial will likely have very few participants, resulting in relatively low costs, but most importantly, that the acquired technology will be advanced in concert with Bioasis's flagship technology, the xB3 Platform.

Never should that PR have allowed any consideration of xB3 weakness. There should have been full confidence expressed about xB3 and that the company will continue to advance xB3 in a vigorous manner.

And saying something like, oh well, investors didn't read it correctly is self-deception. IT IS UP TO THE PR's AUTHORS TO PROPERLY PROJECT THE INTERESTS AND CAPABILITIES OF ITS TECHNOLOGIES AND PROSPECTS.

And the takes that the roadshows and webcasts presented on a move to Nasdaq were certainly less than inspiring. They caused worry about rollbacks and dilution while keeping some important information secret, except for those who accidently saw it.

Amateur stuff. Hubris unbridled.

I support the real things that the company is doing but the news, coupled with projections about Nasdaq, were so poor that the stock actually hit 16¢, enough proof that the presentation, IR and promotion were far from adequate. I don't think it could actually be planned in a manner that could have produced such poor results.

It's time for this operation to buck up and set a tone and image about Bioasis and xB3 that is positive, confident and BIG. And if you can't do it, get some IR who can do it.

And no, the corporate presentation, as I write this, has still not been updated. No mention of Cresence, clinical-stage and the new programs. 

I have to ask the question, if the corporate presentation was updated with the new information, would Bioasis also have to update some other stuff in the presentation that is now outdated and the company doesn't want to reveal it yet? Is that why it's not been updated? Is Bioasis hiding behind apparent procrastination?

But I am generally positive about what could be done. My "Connections" post is positive, and you will learn why some day soon, but there is so much more that can be done.

Yell it from the rooftops, or find somebody with the voice for it!

jd
<< Previous
Bullboard Posts
Next >>